Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin

90-day dosing study is a prerequisite to Phase 3 confirmatory studies under FDA’s BLA

NEW YORK, April 23, 2018 /PRNewswire/ —  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has begun […]

Categories: Press Releases|Tags: |

Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference

NEW YORK, March 27, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences […]

Categories: Press Releases|Tags: |

Oramed to Present at Oppenheimer’s Annual Healthcare Conference

NEW YORK, March 15, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheimer’s 28th Annual Healthcare Conference, being held March 20-21, 2018 […]

Categories: Press Releases|Tags: |

Oramed Adds Two New Members to its Scientific Advisory Board

NEW YORK, Feb. 28, 2018  /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the additions of Drs. Robert Henry and Jane Reusch to its Scientific Advisory Board.

Dr. Henry […]

Categories: Press Releases|Tags: |

Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension

JERUSALEM, Feb. 20, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming CODHy Conference, The 6th World Congress on Controversies […]

Categories: Press Releases|Tags: |

Oramed to Present at BIO CEO Investor Conference

JERUSALEM, Feb. 6, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place February 12-13, […]

Categories: Press Releases|Tags: |

Oramed Pharmaceuticals’ CEO Issues Letter to Shareholders

JERUSALEM, Jan. 19, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com)

Dear Shareholders,

All the hard work and dedication in 2017 has successfully positioned Oramed to initiate a U.S. based multicenter 90-day treatment study under a FDA IND focused on the lowering of HbA1c in […]

Categories: Press Releases|Tags: |

Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule

JERUSALEM, Nov. 14, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel’s Ministry of Health has granted the Company approval to initiate an exploratory clinical study of its […]

Categories: Press Releases|Tags: |

Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins

JERUSALEM, Oct. 31, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the European Patent Office has issued to Oramed a notice of intent to grant a patent for broader […]

Categories: Press Releases|Tags: |

Oramed to Present at the Diabetes Technology Meeting

JERUSALEM, October 24, 2017 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 17th Annual Diabetes Technology Meeting, November 2 to November 4, 2017, […]

Categories: Press Releases|Tags: |